The authors would like to acknowledge all members of the IR-Tox team who contributed to the care of the patients included in this manuscript, and those who referred patients to this pilot program. We extend special thanks to the team members who were not included as co-authors but contributed to the development of this manuscript: Jennifer Mammen, MD; Inbal Sander MD; Joanna Melia, MD; Lyle Ostrow, MD, PhD; Meghan Berkenstock, MD; Alan Baer, MD; Lonny Yarmus, DO; Patricia Brothers, BSN; Anna Ferguson, BSN; Maureen Berg, BSN; Dung T. Le, MD; Kristen A. Marrone, MD; Leisha A. Emens, MD, PhD; William J. Sharfman, MD; and Elizabeth M. Jaffee, MD, PhD.
Lee B, Kim K, Choi JY, . Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: a prospective study. Medicine (Baltimore) 2017;96:e8089.
Wheless SA, McKinney KA, Zanation AM. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol Head Neck Surg 2010;143:650–654.
van Hagen P, Spaander MC, van der Gaast A, . Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study. Int J Clin Oncol 2013;18:214–219.
Kurpad R, Kim W, Rathmell WK, . A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? Urol Oncol 2011;29:378–382.
Schmidt HM, Roberts JM, Bodnar AM, . Thoracic multidisciplinary tumor board routinely impacts therapeutic plans in patients with lung and esophageal cancer: a prospective cohort study. Ann Thorac Surg 2015;99:1719–1724.
- Search Google Scholar
- Export Citation
)| false . , Schmidt HM , Roberts JM , Bodnar AM Thoracic multidisciplinary tumor board routinely impacts therapeutic plans in patients with lung and esophageal cancer: a prospective cohort study. 2015; 99: 1719– 1724. 25678503 10.1016/j.athoracsur.2014.11.019
van der Velden DL, van Herpen CM, van Laarhoven HW, . Molecular tumor boards: current practice and future needs. Ann Oncol 2017;28:3070–3075.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158–168.
Gupta A, De Felice KM, Loftus EV Jr, . Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015;42:406–417.
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed August 24, 2018.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, . Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017;377:1345–1356.
Hellmann MD, Ciuleanu TE, Pluzanski A, . Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018;378:2093–2104.
Motzer RJ, Tannir NM, McDermott DF, . Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277–1290.
Antonia SJ, López-Martin JA, Bendell J, . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883–895.
Neelapu SS, Tummala S, Kebriaei P, . Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47–62.
Zhou C, Crawford A, Serhal E, . The impact of Project ECHO on participant and patient outcomes: a systematic review. Acad Med 2016;91:1439–1461.
Lisberg A, Tucker DA, Goldman JW, . Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center. Cancer Immunol Res 2018;6:288–294.